Stockscreener 앱 받기
10.13
1.27%
-0.13
시간 외 거래:
10.15
0.02
+0.20%
전일 마감가:
$10.26
열려 있는:
$10.33
하루 거래량:
13.07M
Relative Volume:
8.42
시가총액:
$387.71M
수익:
$127.70M
순이익/손실:
$-121.25M
주가수익비율:
-3.2159
EPS:
-3.15
순현금흐름:
$-120.32M
1주 성능:
-2.13%
1개월 성능:
+1.71%
6개월 성능:
+25.68%
1년 성능:
-35.60%
1일 변동 폭
$10.11
$10.47
1주일 범위
$10.11
$10.47
52주 변동 폭
$4.80
$18.13
아이테오스 Stock (ITOS) Company Profile
명칭
Iteos Therapeutics Inc
전화
857-204-4583
주소
321 ARSENAL STREET, WATERTOWN
ITOS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
10.13 | 396.13M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
아이테오스 Stock (ITOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-05-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-05-14 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-05-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-13 | 개시 | Wells Fargo | Overweight |
| 2021-05-05 | 개시 | H.C. Wainwright | Buy |
| 2020-10-08 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | SVB Leerink | Outperform |
| 2020-08-18 | 개시 | Wedbush | Outperform |
모두보기
아이테오스 주식(ITOS)의 최신 뉴스
Securities Law Risks in Biotech M&A: A Closer Look at iTeos Therapeutics' Proposed Acquisition - AInvest
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders - GlobeNewswire Inc.
Rowley Law PLLC Investigates iTeos Therapeutics Acquisition for Securities Law Violations - AInvest
Navigating ITOS Stock: ITeos Therapeutics Inc Journey - investchronicle.com
iTeos Therapeutics To Be Acquired by Concentra Biosciences - citybiz
ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders - The Globe and Mail
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors - Stock Titan
Concentra To Acquire ITeos - Nasdaq
The Strategic Rationale and Valuation Implications of Concentra Biosciences' Acquisition of iTeos Therapeutics - AInvest
iTeos Therapeutics, Inc. Enters Merger Agreement with Concentra Biosciences, LLC for $10.047 per Share Acquisition - Quiver Quantitative
iTeos Therapeutics Enters into Agreement to Be Acquired by - GlobeNewswire
Is iTeos Therapeutics Inc. a good long term investmentConsistent triple returns - PrintWeekIndia
iTeos Therapeutics Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - jammulinksnews.com
What drives iTeos Therapeutics Inc. stock priceDynamic profit expansion - PrintWeekIndia
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones - Informazione.it
What analysts say about iTeos Therapeutics Inc. stockOutstanding trading profits - jammulinksnews.com
What risks could impact iTeos Therapeutics Inc. stock performanceFree Stock Index Interpretation - Newser
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
GSK and Iteos Therapeutics’ Promising Phase 3 Study on NSCLC Treatment - TipRanks
How iTeos Therapeutics Inc. stock performs during market volatilityFree Stock Market Expert Consultation - Newser
What makes iTeos Therapeutics Inc. stock price move sharplyStrategic High Profit Opportunities - Newser
Why iTeos Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Query - Newser
GSK and iTeos Therapeutics Advance Phase 3 NSCLC Study with Belrestotug and Dostarlimab - TipRanks
iTeos Therapeutics (ITOS): An Example of Biotech Liquidations - MSN
iTeos Therapeutics Stock Jumps Following Operational Closure Announcement - MSN
(ITOS) Technical Data - news.stocktradersdaily.com
iTeos Therapeutics CEO Michel Detheux sells $1.59m in stock By Investing.com - Investing.com Nigeria
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Exchange Traded Concepts LLC Acquires 3,468 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics Holds Annual Stockholders Meeting - TipRanks
Stock Performance Spotlight: ITeos Therapeutics Inc (ITOS) Ends the Day at 10.10, Down by -0.69 - DWinneX
Learn to Evaluate (ITOS) using the Charts - news.stocktradersdaily.com
ITeos Therapeutics Insider Sold Shares Worth $1,048,264, According to a Recent SEC Filing - MarketScreener
Bank of America Corp DE Decreases Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Brokerages Set iTeos Therapeutics, Inc. (NASDAQ:ITOS) PT at $15.86 - Defense World
ITeos Therapeutics Insider Sold Shares Worth $1,592,520, According to a Recent SEC Filing - marketscreener.com
iTeos Therapeutics: Navigating Strategic Crossroads Amid Insider Sales and Asset Plays - AInvest
Director David Hallal Sells 114,682 Shares of ITeos Therapeutics Inc (ITOS) - GuruFocus
Squarepoint Ops LLC Sells 18,686 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
아이테오스 (ITOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):